Invacare continues to see increase in demand for respiratory
By HME News Staff
Updated Wed April 15, 2020
ELYRIA, Ohio - Invacare continues to see high demand globally for its respiratory products, beds and therapeutic support surfaces, which it says are vital in the fight against the coronavirus pandemic, the company said in a business update on April 14. The company is working to increase capacity to produce these products and resolve global supply chain challenges compounded by the effects of the pandemic. “As a result, there are practical limits to the extent we can increase output,” said Matthew Monaghan, chairman, president and CEO. “And we are taking steps to offset cost increases from pandemic-related supply chain disruptions.” Invacare is experiencing a global decline in quotes for mobility and seating products, and expects a decline in orders. It expects, however, for demand to rebound once COVID-19 related priority care and public health policies are relaxed. Invacare expects to report unaudited and preliminary net sales of about $218 million for the first quarter of 2020, a 2.2% decrease compared to the same period in 2019. Preliminary results for the quarter were largely ahead of the influence of the coronavirus, and reflect growth in respiratory and mobility and seating products offset by a decline in lifestyle products.
Comments